Development of a fluorogenic small substrate for dipeptidyl peptidase-4

被引：4

作者：

Ogawa, Futa ^{[1
]}

Takeda, Masanori ^{[1
]}

Miyanaga, Kanae ^{[2
]}

Tani, Keita ^{[2
]}

Yamazawa, Ryuji ^{[1
]}

Ito, Kiyoshi ^{[1
]}

Tarui, Atsushi ^{[1
]}

Sato, Kazuyuki ^{[1
]}

Omote, Masaaki ^{[1
]}

机构：

[1] Setsunan Univ, Fac Pharmaceut Sci, 45-1 Nagaotoge Cho, Hirakata, Osaka 5730101, Japan

[2] Osaka Kyoiku Univ, Div Nat Sci, Osaka 5828582, Japan

来源：

BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY | 2017年 / 13卷

关键词：

dipeptidyl peptidase-4; fluorogenic substrate; fluorometry; small fluorescent molecule; SOLID-STATE; FLUORESCENT-PROBE; IN-VIVO; CELLS; DESIGN; VIOLET; TUMOR; IV;

D O I：

10.3762/bjoc.13.267

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

A series of aniline and m-phenylenediamine derivatives with electron-withdrawing 3,3,3-trifluoropropenyl substituents were synthesized as small and chemically stable fluorescent organic compounds. Their fluorescence performances were evaluated by converting 2,4-disubstituted aniline 1 to the non-fluorescent dipeptide analogue H-Gly-Pro-1 for the use as a fluorogenic substrate for dipeptidyl peptidase-4 (DPP-4). The progress of the enzymatic hydrolysis of H-Gly-Pro-1 with DPP-4 was monitored by fluorometric determination of 1 released into the reaction medium. The results suggest that 1 could be used as fluorophore in OFF-ON-type fluorogenic probes.

引用

页码：2690 / 2697

页数：8

共 50 条

[31] Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, Larry K.
Drayna, Caitlin C.
McDermott, Michael T.
CLINICAL PHARMACOKINETICS, 2012, 51 (08) : 501 - 514
[32] The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes
O'Hara, Daniel V.
Parkhill, Thomas R.
Badve, Sunil V.
Jun, Min
Jardine, Meg J.
Perkovic, Vlado
DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 763 - 773
[33] Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B.
Marcoviciu, D.
Dicker, D.
CURRENT CARDIOLOGY REPORTS, 2013, 15 (08)
[34] Effect of dipeptidyl peptidase-4 inhibition on complement activation
Hoffmann-Petersen, Ingeborg
Ostergaard, Jakob Appel
Holt, Charlotte Berg
Mellbin, Linda
Thiel, Steffen
Hansen, Troels Krarup
MOLECULAR IMMUNOLOGY, 2015, 67 (01) : 144 - 144
[35] Vildagliptin:: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
Ahrén, B
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (04) : 431 - 442
[36] Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
Kim, Kwang-il
KOREAN CIRCULATION JOURNAL, 2018, 48 (05) : 430 - 432
[37] Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Huang, Jie
Liu, Xinxin
Wei, Yingying
Li, Xinlu
Gao, Shupei
Dong, Lingli
Rao, Xiaoquan
Zhong, Jixin
FRONTIERS IN IMMUNOLOGY, 2022, 13
[38] Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
Deacon, C. F.
Lebovitz, H. E.
DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 333 - 347
[39] Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
Trzaskalski, Natasha A.
Fadzeyeva, Evgenia
Mulvihill, Erin E.
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2020, 13
[40] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
Marina Rankovic
Nevena Jeremic
Ivan Srejovic
Katarina Radonjic
Aleksandra Stojanovic
Milos Glisic
Stefani Bolevich
Sergey Bolevich
Vladimir Jakovljevic
Heart Failure Reviews, 2021, 26 : 437 - 450

← 1 2 3 4 5 →